Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEXGEN-PD vaccine
- Development stage
- Preclinical
- Lead developer
- Tridem Bioscience
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
NEXGEN-PD is an experimental therapeutic vaccine for Parkinson's disease currently in preclinical development. Developed by a European consortium led by Tridem Bioscience (coordinator) and including KINETO Lab (responsible for in vivo testing), the vaccine utilizes the proprietary WISIT (Whole Immune System Targeting) platform. This platform belongs to a novel class of gluconeoconjugate vaccines (GNCVs) designed for intradermal administration. The vaccine specifically targets alpha-synuclein (aSyn) aggregates, aiming to leverage skin-resident dendritic cells to generate a potent and specific immune response to clear pathological protein aggregates, potentially offering a disease-modifying treatment for Parkinson's disease. The project is funded by the European Union's Horizon Europe research and innovation program.
- Other names
- WISIT vaccineNEXGEN PDNEXGEN PD (skin immunity platform)
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on NEXGEN-PD vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEXGEN-PD vaccine.